COLL - Collegium Pharmaceutical Inc logo

Collegium Pharmaceutical Inc

COLL

Collegium Pharmaceutical develops and commercializes medications for pain management, including extended-release opioids and a CNS stimulant for ADHD. Their products aim to address severe and persistent pain while minimizing abuse risks through innovative delivery methods.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$1,255today

Score Overview

1 Year
Score
Net Growth-23.79%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth3.54%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.6
Net Growth-33.00%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth191.91%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth150.88%
Net Trend70%
Net Income Consistency
Rev Growthโ€”
Rev Trend89%
Revenue Consistency
All Time
Scoreโ€”
Net Growth275.80%
Net Trend64%
Net Income Consistency
Rev Growthโ€”
Rev Trend89%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Collegium Pharmaceutical Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. COLL does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 22.96โ€”
1 Year2025-10-23
$ 35.54-35.40%
5 Years2021-10-22
$ 21.069.02%
10 Years2016-10-21
$ 18.3025.46%
All Time2015-05-07
$ 12.2986.82%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 808M$ 47M$ 129M
2025$ 780M$ 62M$ 406M
2024$ 631M$ 69M$ 162M
2023$ 566M$ 48M$ 310M
2022$ 463M-$ 25M$ 173M
2021$ 276M$ 71M$ 186M
2020$ 310M$ 26M$ 174M
2019$ 296M-$ 22M$ 170M
2018$ 280M-$ 39M$ 146M
2017$ 28M-$ 74M$ 118M
2016-$ 94M$ 153M
IPO2015$ 0.00-$ 27M$ 95M
COLL - Collegium Pharmaceutical Inc logo

Collegium Pharmaceutical Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 310M to $ 780M and net income grew from $ 26M to $ 62M. Revenue increased in every one of those 5 years; net income in 2.

Collegium Pharmaceutical Inc currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.

Membership

Explore COLL with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies